FDA ap­proves Re­gen­eron's an­ti­body for rare im­mune dis­ease, re­solves man­u­fac­tur­ing is­sues for afliber­cept

The FDA ap­proved Re­gen­eron’s poze­limab, the first treat­ment for a rare, hered­i­tary im­mune dis­ease that af­fects few­er than 100 peo­ple world­wide.

The mon­o­clon­al an­ti­body, to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER